Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,279 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: Human Immunodeficiency Virus
Interventions: Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 59 Years · Male only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Spirometry
Interventions: Community health worker-delivered multi-component respiratory health intervention; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 9 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections, Cytopenias
Interventions: Filgrastim; Drug
Lead sponsor: Amgen; Industry
Eligibility: 13 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more

Conditions: HIV/AIDS
Interventions: Skill-Building (SB) plus Motivational Interviewing, Skill-Building (SB); Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 19 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Surgical Site Infection, Cesarean Section; Complications, Wound, Infection (Following Delivery), Postpartum Complication
Interventions: Steri3X, Control; Device · Other
Lead sponsor: University of Tennessee; Other
Eligibility: 16 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Yellow Fever
Interventions: XRX-001 Inactivated yellow fever vaccine, Placebo; Biological
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: HIV Infections, Sexually Transmitted Disease
Interventions: Eban HIV/STD Risk Reduction Intervention, Eban Health Promotion Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 1,070 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 4
States / cities: Los Angeles, California • Atlanta, Georgia • New York, New York + 1 more

Conditions: HIV/AIDS
Interventions: Making PrEP Smart; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Nystatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Birmingham, Alabama • Princeton, New Jersey

Conditions: Hiv, Opioid Use Disorder
Interventions: community-friendly health recovery program, Pre-Exposure Prophylaxis and Post-Exposure Prophylaxis; Behavioral · Drug
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Influenza, Healthy
Interventions: FluMist trivalent (2015-2016), FluMist Quadrivalent (2015-2016), FluMist Quadrivalent (2017-2018); Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 24 Months to 47 Months
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 12
States / cities: Savannah, Georgia • Bardstown, Kentucky • St Louis, Missouri + 9 more

Conditions: Open Fracture
Interventions: Not listed
Lead sponsor: Olayemi Osiyemi MD; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: HIV Infection
Interventions: Emtricitabine/tenofovir disoproxil; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 15 Years to 22 Years · Male only
Enrollment: 167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more

Conditions: Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus
Interventions: Daptomycin, Vancomycin; Drug
Lead sponsor: Mountain Home Research & Education Corporation; Other
Eligibility: 18 Years to 90 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Johnson City, Tennessee • Mountain Home, Tennessee

Conditions: Influenza, COVID-19
Interventions: Provider communication training; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 24,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: COVID-19, SARS-CoV-2
Interventions: AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 3,882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 130
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more

Conditions: Respiratory Syncytial Virus Infection
Interventions: RSV Polyclonal Immunoglobulin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: CMV
Interventions: Brincidofovir, Placebo; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 39
States / cities: La Jolla, California • Los Angeles, California • Denver, Colorado + 25 more

Conditions: Clostridioides Difficile Infection
Interventions: Health counseling sessions, Diet (control diet), Diet (experimental diet); Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pars Plana Vitrectomy, Scleral Buckling, Surgical Outcomes, Infection Prophylaxis
Interventions: Not listed
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: COVID-19, Corona Virus Infection, ARDS, Acute Respiratory Distress Syndrome
Interventions: Hydroxychloroquine, Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 1,483 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Minneapolis, Minnesota

Conditions: HIV, Acquired Immunodeficiency Syndrome, Alcoholism, Alcoholic Intoxication, Substance-Related Disorders
Interventions: Motivational Interviewing, Email Feedback, Usual Care; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 100 Years
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prevention of COVID-19
Interventions: Resistance Exercise; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Garfield Heights, Ohio

Conditions: Infections
Interventions: Cefazolin 3gm for Injection USP and Dextrose Injection USP; Drug
Lead sponsor: B. Braun Medical Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Columbus, Georgia • Oklahoma City, Oklahoma

Search by objective public record fields.

Biomarkers for Event-driven PrEP Adherence

The INTERvening for LUNG Health Trial

A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.

Improving HIV Prevention Skills in People With Serious Mental Illnesses

The Use of Steri3X for Prevention of Post-operative Wound Infections in Cesarean Sections

Trial of Yellow Fever Inactivated Vaccine

Effectiveness of a Risk Reduction Program in Preventing the Transmission of HIV and Sexually Transmitted Diseases in African-American Couples

Making PrEP Smart: An HIV Testing and PrEP Electronic Support Tool ("SmartPrEP" App) for Women on PrEP

A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes

Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age

Preventing Infections in Orthopaedic Patients

Factors Affecting PrEP Adherence

Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty

Patient-Centered Practical Vaccine Talk For Busy Clinicians

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

Prevention of RSV Infections in Bone Marrow Transplant Recipients

A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients

Lifestyle and Recurrent Clostridioides Difficile Infection (CDI)

Necessity of Post-operative Eye Drops

Pre-exposure Prophylaxis for SARS-Coronavirus-2

Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients

Effects of Surgical Mask Use on Peak Torque, Total Work and Interset Fatigability During Isokinetic Strength Testing

Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults